AstraZeneca (NYSE:AZN) and collaboration partner Merck (NYSE:MRK) announce that China’s National Medical Products Administration has approved Lynparza (olaparib) for the first-line maintenance treatment of adult patients with newly diagnosed advanced germline or somatic BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemo.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.